194 related articles for article (PubMed ID: 18027989)
1. Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Joerger M; Huitema AD; Richel DJ; Dittrich C; Pavlidis N; Briasoulis E; Vermorken JB; Strocchi E; Martoni A; Sorio R; Sleeboom HP; Izquierdo MA; Jodrell DI; Féty R; de Bruijn E; Hempel G; Karlsson M; Tranchand B; Schrijvers AH; Twelves C; Beijnen JH; Schellens JH;
Clin Pharmacokinet; 2007; 46(12):1051-68. PubMed ID: 18027989
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and its relation to toxicity of pegylated-liposomal doxorubicin in Chinese patients with breast tumours.
Xu L; Wang W; Sheng YC; Zheng QS
J Clin Pharm Ther; 2010 Oct; 35(5):593-601. PubMed ID: 20831683
[TBL] [Abstract][Full Text] [Related]
5. Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array.
Kalra S; Kaur RP; Ludhiadch A; Shafi G; Vashista R; Kumar R; Munshi A
Eur J Clin Pharmacol; 2018 Oct; 74(10):1291-1298. PubMed ID: 29938344
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced subacute lupus erythematosus.
Guhl G; Diaz-Ley B; García-García C; Fraga J; Garcia-Diez A
Lupus; 2009 Aug; 18(9):859-60. PubMed ID: 19578115
[No Abstract] [Full Text] [Related]
7. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
9. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao S; Barlow WE; Albain KS; Choi JY; Zhao H; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff M; Hortobagyi GN; Hayes DF; Ambrosone CB
Clin Cancer Res; 2010 Dec; 16(24):6169-76. PubMed ID: 21169260
[TBL] [Abstract][Full Text] [Related]
10. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer.
Petros WP; Broadwater G; Berry D; Jones RB; Vredenburgh JJ; Gilbert CJ; Gibbs JP; Colvin OM; Peters WP
Clin Cancer Res; 2002 Mar; 8(3):698-705. PubMed ID: 11895898
[TBL] [Abstract][Full Text] [Related]
11. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity.
Fan L; Goh BC; Wong CI; Sukri N; Lim SE; Tan SH; Guo JY; Lim R; Yap HL; Khoo YM; Iau P; Lee HS; Lee SC
Pharmacogenet Genomics; 2008 Jul; 18(7):621-31. PubMed ID: 18551042
[TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
13. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy.
Kirshner J; Hatch M; Hennessy DD; Fridman M; Tannous RE
Oncologist; 2004; 9(1):25-32. PubMed ID: 14755012
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer.
Swenson CE; Bolcsak LE; Batist G; Guthrie TH; Tkaczuk KH; Boxenbaum H; Welles L; Chow SC; Bhamra R; Chaikin P
Anticancer Drugs; 2003 Mar; 14(3):239-46. PubMed ID: 12634619
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
17. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma.
Lyass O; Uziely B; Ben-Yosef R; Tzemach D; Heshing NI; Lotem M; Brufman G; Gabizon A
Cancer; 2000 Sep; 89(5):1037-47. PubMed ID: 10964334
[TBL] [Abstract][Full Text] [Related]
18. Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer.
Moreira A; Lobato R; Morais J; Silva S; Ribeiro J; Figueira A; Vale D; Sousa C; Araújo F; Fernandes A; Oliveira J; Passos-Coelho JL
Cancer Chemother Pharmacol; 2001 Oct; 48(4):333-7. PubMed ID: 11710635
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.
Liang S; Brundage RC; Jacobson PA; Blaes A; Kirstein MN
Br J Clin Pharmacol; 2016 Sep; 82(3):773-83. PubMed ID: 27128712
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]